miltefosine has been researched along with Acanthamoeba Keratitis in 17 studies
miltefosine: hexadecyl phosphocholine derivative of cisplatin; did not substantially activate HIV long terminal repeat; less toxic than cisplatin
miltefosine : A phospholipid that is the hexadecyl monoester of phosphocholine.
Acanthamoeba Keratitis: Infection of the cornea by an ameboid protozoan which may cause corneal ulceration leading to blindness.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Acanthamoeba castellanii genotype T4 was obtained from a patient with keratitis and subjected to in vitro susceptibility testing with various antimicrobial agents, including Chlorhexidine (CHX), Pentamidine isethionate (PI)Polyhexamethylene biguanide (PHMB), and Miltefosine to assess their efficacy against Acanthamoeba trophozoites and cyst." | 8.31 | Comparing cytotoxicity and efficacy of miltefosine and standard antimicrobial agents against Acanthamoeba trophozoites and cyst forms: An in vitro study. ( Kazemirad, E; Latifi, A; Mohebali, M; Rezaian, M; Soleimani, M; Yasami, S, 2023) |
| "The purpose of this study was to report a retrospective case series of anterior scleral and limbal inflammatory necrosis after adjuvant miltefosine for recalcitrant Acanthamoeba keratitis (AK)." | 8.12 | Anterior Scleral and Limbal Inflammatory Necrosis After Adjuvant Miltefosine for Recalcitrant Acanthamoeba Keratitis. ( Berdahl, J; de la Presa, M; Holland, EJ; Ibach, M, 2022) |
| "To report a case series of patients with treatment-resistant Acanthamoeba keratitis (AK) using oral miltefosine, often as salvage therapy." | 8.02 | Oral Miltefosine as Salvage Therapy for Refractory Acanthamoeba Keratitis. ( Appenheimer, AB; Chodosh, J; Hou, JH; Kang, JJ; Morrill, AM; Rapuano, CJ; Saeed, HN; Thulasi, P; Tu, EY; Vyas, N; Zegans, ME; Zuckerman, R, 2021) |
| "This case shows resolution of recalcitrant Acanthamoeba keratitis with oral miltefosine in an immunocompetent patient." | 7.91 | Oral Miltefosine as Adjunctive Treatment for Recalcitrant Acanthamoeba Keratitis. ( Dewan, N; Holland, SP; Iovieno, A; Ming, W; Yeung, SN, 2019) |
| "In this study, a series of compounds - miltefosine, polyhexamethylene biguanide, chlorhexidine and propamidine isethionate - and combinations of the latter three agents with miltefosine were prepared and used in a rat model for the topical treatment of Acanthamoeba keratitis." | 7.80 | Miltefosine and polyhexamethylene biguanide: a new drug combination for the treatment of Acanthamoeba keratitis. ( Arici, MK; Dursun, A; Obwaller, A; Polat, ZA; Vural, A; Walochnik, J, 2014) |
| "Miltefosine treatment yielded much higher cure scores than propamidine isetionate plus polyhexanide." | 5.38 | Efficacy of miltefosine for topical treatment of Acanthamoeba keratitis in Syrian hamsters. ( Obwaller, A; Polat, ZA; Vural, A; Walochnik, J, 2012) |
| "The treatment of Acanthamoeba keratitis has now been possible since the first successful therapy developed in the mid 1980s with a combination of propamidine 0." | 4.82 | Treatment of Acanthamoeba keratitis. ( Seal, D, 2003) |
| "The purpose of this study was to describe the management of a case of recurrent scleritis and Acanthamoeba -positive scleral abscess in a patient after the use of miltefosine for recalcitrant Acanthamoeba keratitis." | 4.31 | Successful Medical and Surgical Management of Recalcitrant Acanthamoeba Keratitis, Scleritis, and Culture-Positive Scleral Abscess. ( Davis, A; Heath, M; Riaz, KM, 2023) |
| " Acanthamoeba castellanii genotype T4 was obtained from a patient with keratitis and subjected to in vitro susceptibility testing with various antimicrobial agents, including Chlorhexidine (CHX), Pentamidine isethionate (PI)Polyhexamethylene biguanide (PHMB), and Miltefosine to assess their efficacy against Acanthamoeba trophozoites and cyst." | 4.31 | Comparing cytotoxicity and efficacy of miltefosine and standard antimicrobial agents against Acanthamoeba trophozoites and cyst forms: An in vitro study. ( Kazemirad, E; Latifi, A; Mohebali, M; Rezaian, M; Soleimani, M; Yasami, S, 2023) |
| "The purpose of this study was to report a retrospective case series of anterior scleral and limbal inflammatory necrosis after adjuvant miltefosine for recalcitrant Acanthamoeba keratitis (AK)." | 4.12 | Anterior Scleral and Limbal Inflammatory Necrosis After Adjuvant Miltefosine for Recalcitrant Acanthamoeba Keratitis. ( Berdahl, J; de la Presa, M; Holland, EJ; Ibach, M, 2022) |
| "To report a case series of patients with treatment-resistant Acanthamoeba keratitis (AK) using oral miltefosine, often as salvage therapy." | 4.02 | Oral Miltefosine as Salvage Therapy for Refractory Acanthamoeba Keratitis. ( Appenheimer, AB; Chodosh, J; Hou, JH; Kang, JJ; Morrill, AM; Rapuano, CJ; Saeed, HN; Thulasi, P; Tu, EY; Vyas, N; Zegans, ME; Zuckerman, R, 2021) |
| "This case shows resolution of recalcitrant Acanthamoeba keratitis with oral miltefosine in an immunocompetent patient." | 3.91 | Oral Miltefosine as Adjunctive Treatment for Recalcitrant Acanthamoeba Keratitis. ( Dewan, N; Holland, SP; Iovieno, A; Ming, W; Yeung, SN, 2019) |
| "In this study, a series of compounds - miltefosine, polyhexamethylene biguanide, chlorhexidine and propamidine isethionate - and combinations of the latter three agents with miltefosine were prepared and used in a rat model for the topical treatment of Acanthamoeba keratitis." | 3.80 | Miltefosine and polyhexamethylene biguanide: a new drug combination for the treatment of Acanthamoeba keratitis. ( Arici, MK; Dursun, A; Obwaller, A; Polat, ZA; Vural, A; Walochnik, J, 2014) |
| "Miltefosine treatment yielded much higher cure scores than propamidine isetionate plus polyhexanide." | 1.38 | Efficacy of miltefosine for topical treatment of Acanthamoeba keratitis in Syrian hamsters. ( Obwaller, A; Polat, ZA; Vural, A; Walochnik, J, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (17.65) | 29.6817 |
| 2010's | 5 (29.41) | 24.3611 |
| 2020's | 9 (52.94) | 2.80 |
| Authors | Studies |
|---|---|
| de la Presa, M | 1 |
| Ibach, M | 1 |
| Berdahl, J | 1 |
| Holland, EJ | 1 |
| Heath, M | 1 |
| Riaz, KM | 1 |
| Davis, A | 1 |
| Latifi, A | 1 |
| Mohebali, M | 1 |
| Yasami, S | 1 |
| Soleimani, M | 1 |
| Rezaian, M | 1 |
| Kazemirad, E | 1 |
| Avdagic, E | 1 |
| Chew, HF | 1 |
| Veldman, P | 1 |
| Tu, EY | 3 |
| Jafri, M | 1 |
| Doshi, R | 1 |
| Boggild, AK | 1 |
| Reidy, JJ | 2 |
| Farooq, AV | 2 |
| Thulasi, P | 2 |
| Saeed, HN | 1 |
| Rapuano, CJ | 1 |
| Hou, JH | 1 |
| Appenheimer, AB | 1 |
| Chodosh, J | 1 |
| Kang, JJ | 1 |
| Morrill, AM | 1 |
| Vyas, N | 1 |
| Zegans, ME | 1 |
| Zuckerman, R | 1 |
| Si, Z | 1 |
| Veldman, PB | 1 |
| Kaur, A | 1 |
| Sahu, SK | 1 |
| Matoba, A | 1 |
| Weikert, MP | 1 |
| Kim, S | 1 |
| Bagga, B | 1 |
| Joseph, J | 1 |
| Garg, P | 1 |
| Chandran, K | 1 |
| Jayabhasker, P | 1 |
| Manjulatha, K | 1 |
| Sharma, S | 1 |
| Dewan, N | 1 |
| Ming, W | 1 |
| Holland, SP | 1 |
| Yeung, SN | 1 |
| Iovieno, A | 1 |
| Polat, ZA | 2 |
| Walochnik, J | 3 |
| Obwaller, A | 3 |
| Vural, A | 2 |
| Dursun, A | 1 |
| Arici, MK | 1 |
| Mrva, M | 1 |
| Garajová, M | 1 |
| Lukáč, M | 1 |
| Ondriska, F | 1 |
| Seal, D | 1 |
| Vasseneix, C | 1 |
| Gargala, G | 1 |
| François, A | 1 |
| Hellot, MF | 1 |
| Duclos, C | 1 |
| Muraine, M | 1 |
| Benichou, J | 1 |
| Ballet, JJ | 1 |
| Brasseur, G | 1 |
| Favennec, L | 1 |
| Duchêne, M | 1 |
| Seifert, K | 1 |
| Hottkowitz, T | 1 |
| Wiedermann, G | 1 |
| Eibl, H | 1 |
| Aspöck, H | 1 |
1 review available for miltefosine and Acanthamoeba Keratitis
| Article | Year |
|---|---|
Treatment of Acanthamoeba keratitis.
Topics: Acanthamoeba Keratitis; Amebicides; Anti-Bacterial Agents; Anti-Infective Agents, Local; Antiprotozo | 2003 |
16 other studies available for miltefosine and Acanthamoeba Keratitis
| Article | Year |
|---|---|
Anterior Scleral and Limbal Inflammatory Necrosis After Adjuvant Miltefosine for Recalcitrant Acanthamoeba Keratitis.
Topics: Acanthamoeba Keratitis; Adjuvants, Immunologic; Adult; Humans; Inflammation; Necrosis; Phosphorylcho | 2022 |
Successful Medical and Surgical Management of Recalcitrant Acanthamoeba Keratitis, Scleritis, and Culture-Positive Scleral Abscess.
Topics: Abscess; Acanthamoeba; Acanthamoeba Keratitis; Female; Humans; Scleral Diseases; Scleritis | 2023 |
Comparing cytotoxicity and efficacy of miltefosine and standard antimicrobial agents against Acanthamoeba trophozoites and cyst forms: An in vitro study.
Topics: Acanthamoeba; Acanthamoeba Keratitis; Animals; Anti-Infective Agents; Chlorhexidine; Chlorocebus aet | 2023 |
Resolution of
Topics: Acanthamoeba; Acanthamoeba Keratitis; Administration, Oral; Adult; Antiprotozoal Agents; Cornea; DNA | 2021 |
Oral Miltefosine as Salvage Therapy for Refractory Acanthamoeba Keratitis.
Topics: Acanthamoeba Keratitis; Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antiprotoz | 2021 |
Severe Inflammatory Response in a Patient on Oral Miltefosine for Acanthamoeba Keratitis.
Topics: Acanthamoeba; Acanthamoeba Keratitis; Humans; Phosphorylcholine | 2022 |
Comment on "Oral Miltefosine as Salvage Therapy for Refractory Acanthamoeba Keratitis".
Topics: Acanthamoeba; Acanthamoeba Keratitis; Humans; Phosphorylcholine; Salvage Therapy | 2021 |
Reply to Comment on "Oral Miltefosine as Salvage Therapy for Recalcitrant Acanthamoeba Keratitis".
Topics: Acanthamoeba; Acanthamoeba Keratitis; Humans; Phosphorylcholine; Salvage Therapy | 2021 |
Corneal Manifestations of Miltefosine Toxicity in Acanthamoeba Keratitis.
Topics: Acanthamoeba Keratitis; Anti-Allergic Agents; Antiprotozoal Agents; Corneal Stroma; Drug Substitutio | 2021 |
Efficacy of Topical Miltefosine in Patients with Acanthamoeba Keratitis: A Pilot Study.
Topics: Acanthamoeba; Acanthamoeba Keratitis; Adult; Animals; Antiprotozoal Agents; Cornea; Eye Infections, | 2019 |
Oral Miltefosine as Adjunctive Treatment for Recalcitrant Acanthamoeba Keratitis.
Topics: Acanthamoeba Keratitis; Administration, Oral; Adult; Antiprotozoal Agents; Chemotherapy, Adjuvant; C | 2019 |
Miltefosine and polyhexamethylene biguanide: a new drug combination for the treatment of Acanthamoeba keratitis.
Topics: Acanthamoeba; Acanthamoeba Keratitis; Animals; Antiprotozoal Agents; Biguanides; Cell Line; Cell Pro | 2014 |
Weak cytotoxic activity of miltefosine against clinical isolates of Acanthamoeba spp.
Topics: Acanthamoeba; Acanthamoeba castellanii; Acanthamoeba Keratitis; Antiprotozoal Agents; Cornea; Dose-R | 2011 |
Efficacy of miltefosine for topical treatment of Acanthamoeba keratitis in Syrian hamsters.
Topics: Acanthamoeba; Acanthamoeba Keratitis; Administration, Topical; Animals; Antiprotozoal Agents; Benzam | 2012 |
A keratitis rat model for evaluation of anti-Acanthamoeba polyphaga agents.
Topics: Acanthamoeba; Acanthamoeba Keratitis; Administration, Topical; Animals; Antiprotozoal Agents; Benzam | 2006 |
Cytotoxic activities of alkylphosphocholines against clinical isolates of Acanthamoeba spp.
Topics: Acanthamoeba; Acanthamoeba Keratitis; Alkanes; Amebicides; Animals; Cell Survival; Hexokinase; Human | 2002 |